Jenscare Scientific Co Ltd (9877) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Jenscare Scientific Co Ltd HK$1.44, price HK$7.40, upside -80.5%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jenscare Scientific Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
48‑month range HK$1.80 – HK$66.10 · fair‑value band HK$0.9500 – HK$1.80 · the HK$7.40 price screens above the HK$1.44 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Jenscare Scientific Co in your weekly email
Every Wednesday you see whether Jenscare Scientific Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People's Republic of China.
Show more
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People's Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; Ken-Valve, a TRVR system for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve intervention (TMVR) repair system to treat patients with severe mitral regurgitation; JensRelive, a TMVR system to treat patients with severe mitral regurgitation and replace dysfunctional primary mitral valves without undergoing routine thoracotomy surgery; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it offers platform technologies/accessories comprising introducer kit, JeniGal anti-calcification technology, dry-tissue technology and polymer leaflet technology; and engages in consulting and investment activities. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
Stock analysis
Jenscare Scientific Co Ltd (9877) currently trades at HK$7.40, while our model-based Fair Value estimate is HK$1.44, 80.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the evidence level at low.
Scenario range: HK$0.9500 (bear) to HK$1.80 (bull), the price of HK$7.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Jenscare Scientific Co Ltd reported revenue of 88.2M CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −264M CNY in FY2025.
Key figures
Market cap HK$3.1B (≈ $393M) · P/S ratio 32.7 · EPS (TTM) HK$−0.4100 · Net margin −299% · Return on equity −32.3% · Return on assets (EBIT) −26.3% · Operating margin −121% · Revenue (TTM) HK$90.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −81%, 9877 screens richer than that median.
Fair Value models
Bear HK$0.9500Fair Value HK$1.44Bull HK$1.80
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Jenscare Scientific Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−80.5% · Bottom 25%
Profitability
Return on assets−15.0% · Bottom 25%
Operating margin (TTM)−120.7% · Bottom 25%
Growth and dividend
Revenue growth0.0% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.50× · Cheapest 25%
P/S (TTM)4.34× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 4
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 8
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jenscare Scientific Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/9877
Frequently asked questions
Is Jenscare Scientific Co Ltd (9877) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.44 versus a price of HK$7.40, about −81% upside (overvalued).
What is the fair value of 9877?
Our model-based fair value for Jenscare Scientific Co Ltd is HK$1.44 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$7.40.
What is the quality score of 9877?
Jenscare Scientific Co Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jenscare Scientific Co Ltd (9877)?
Our model-based price target is the fair value of HK$1.44 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.9500, optimistic scenario HK$1.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Jenscare Scientific Co Ltd stock forecast for 2026?
Our models put fair value at HK$1.44, about −81% upside versus a price of HK$7.40 (overvalued). Cautious scenario HK$0.9500, optimistic scenario HK$1.80. The calculation is refreshed regularly with new filings.
What is the revenue of Jenscare Scientific Co Ltd (9877)?
Jenscare Scientific Co Ltd reported trailing-twelve-month revenue of about HK$90.6M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Jenscare Scientific Co Ltd (9877)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jenscare Scientific Co Ltd it is HK$1.44 per share (as of Sep 27, 2026), against a price of HK$7.40. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Jenscare Scientific Co Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 9877 trades above its calculated fair value: price HK$7.40, fair value HK$1.44, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9877?
No. The price is what the market pays today (HK$7.40); the fair value is what the company's own numbers justify (HK$1.44). For Jenscare Scientific Co Ltd the two are HK$5.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jenscare Scientific Co Ltd worth?
The market values Jenscare Scientific Co Ltd at about HK$3.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$7.40; our models calculate a fair value of HK$1.44 per share.
What do the bullish and bearish scenarios say about 9877?
Our models span a range for Jenscare Scientific Co Ltd: cautious scenario HK$0.9500, base HK$1.44, optimistic HK$1.80 per share (as of Sep 27, 2026, price HK$7.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jenscare Scientific Co Ltd (9877)?
Balance-sheet figures for Jenscare Scientific Co Ltd (as of Sep 27, 2026): return on equity −32.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 9877 from its 52-week high?
Jenscare Scientific Co Ltd trades at HK$7.40, about 38% below its 52-week high of HK$11.98 and 9% above the low of HK$6.77 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.44 is for.
Which stocks are comparable to Jenscare Scientific Co Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jenscare Scientific Co Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$7.40, calculated fair value HK$1.44 (−81%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9877 calculated?
We run Jenscare Scientific Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.44, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Jenscare Scientific Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jenscare Scientific Co Ltd (9877)?
The closing price on Sep 30, 2026 was HK$7.40. Our model-based fair value is HK$1.44, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jenscare Scientific Co Ltd right now?
The price sits above even our optimistic bull case (HK$1.80). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.9500 to HK$1.80) leaves room in how you read the outcome.
Key figures of Jenscare Scientific Co Ltd
How large is the market capitalisation of Jenscare Scientific Co Ltd (9877)?
The market capitalisation of Jenscare Scientific Co Ltd is HK$3.1B (≈ $393M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jenscare Scientific Co Ltd (9877)?
The price-to-sales ratio of Jenscare Scientific Co Ltd is 32.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jenscare Scientific Co Ltd (9877)?
Earnings per share at Jenscare Scientific Co Ltd are HK$−0.4100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Jenscare Scientific Co Ltd (9877)?
The net margin of Jenscare Scientific Co Ltd is −299% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jenscare Scientific Co Ltd (9877)?
The return on equity (ROE) of Jenscare Scientific Co Ltd is −32.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jenscare Scientific Co Ltd (9877)?
On an EBIT basis the return on assets of Jenscare Scientific Co Ltd is −26.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jenscare Scientific Co Ltd (9877)?
The operating margin of Jenscare Scientific Co Ltd is −121% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Jenscare Scientific Co Ltd (9877) generate?
The free cash flow of Jenscare Scientific Co Ltd is −HK$80.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jenscare Scientific Co Ltd (9877) hold?
Jenscare Scientific Co Ltd holds more cash than debt, HK$460M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jenscare Scientific Co Ltd in the live analysis
One click puts Jenscare Scientific Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
